Sangamo Therapeutics (SGMO) Receiving Somewhat Favorable Media Coverage, Study Shows
News headlines about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.5487190289253 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- The Sangamo Therapeutics, Inc. (SGMO) Receives $10.25 Consensus PT from Analysts (wisdomsave.com)
- Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significantly Higher Trading Volume (techkenyot.com)
- Sangamo Therapeutics, Inc. (SGMO) Earns Outperform Rating from Wells Fargo & Company (americanbankingnews.com)
- Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Traded Much Higher Than Its 50 Day Moving Average (highlightpress.com)
- Today’s Research Reports on Stocks to Watch: Sangamo Therapuetics and Nutanix (finance.yahoo.com)
A number of equities research analysts recently issued reports on SGMO shares. Wedbush reiterated a “neutral” rating and set a $4.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine upgraded shares of Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. Finally, BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $14.20.
Shares of Sangamo Therapeutics (NASDAQ SGMO) opened at 13.30 on Tuesday. The company’s market cap is $1.11 billion. The firm’s 50-day moving average is $10.52 and its 200-day moving average is $7.34. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $15.05.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $8.30 million during the quarter, compared to the consensus estimate of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business’s quarterly revenue was up 124.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. Analysts expect that Sangamo Therapeutics will post ($0.82) EPS for the current fiscal year.
In other news, VP Curt A. Herberts III sold 11,474 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $10.44, for a total value of $119,788.56. Following the completion of the transaction, the vice president now owns 23,991 shares of the company’s stock, valued at $250,466.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the transaction, the vice president now directly owns 35,517 shares of the company’s stock, valued at approximately $355,170. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,474 shares of company stock valued at $494,789. Insiders own 8.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/12/sangamo-therapeutics-sgmo-receiving-somewhat-favorable-media-coverage-study-shows.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Stock Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related stocks with our FREE daily email newsletter.